Kombucha in Overweight and Obese: Live Vs. Pasteurized Effects on Microbiota, Metabolism, and Liver Function
Recruiting · NCT06759324 · Interventional (participants receive a specific treatment) · Lead sponsor: Associação Centro de Apoio Tecnológico Agro Alimentar
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Kombucha, a fermented beverage made from Camellia sinensis tea (black, oolong, or green) with sugar and a symbiotic culture of bacteria and yeast (SCOBY), has gained global attention for its potential health benefits. Factors like the type and amount of sugar substrate, fermentation time, and temperature significantly influence its organic compounds, total phenolics, vitamin content, and alcohol levels. In a previous study, kombucha's impact on glucose tolerance, insulin sensitivity, body composition, and liver function was tested in male prediabetic mice with diet-induced obesity. Daily supplementation (200 µL per mouse) improved glucose tolerance after nine days (equivalent to one year in humans) and reduced liver steatosis, despite no changes in body composition. Although kombucha has been associated with antioxidant, antimicrobial, probiotic, antidiabetic, and anticancer activities, strong scientific evidence in humans remains limited. Further clinical studies are needed to substantiate kombucha's health benefits in humans.
Who can take part
Inclusion criteria
- Individuals with a Body Mass Index (BMI) between 25 kg/m² and 34.9 kg/m², of both biological sexes, aged between 18 and 60 years, available to comply with the study protocol (described in this document) and sign informed consent.
Exclusion criteria
- Volunteers will be excluded from the study if they present one or more of the following conditions:
- Subjects with sensitivity to kombucha;
- Consumption of kombucha, kefir, kimchi, cheese, raw vinegar, sauerkraut, kvass, and other fermented products during the study and in the 3 weeks before the study.
- Use of antibiotics in the 6 months prior to the start of the study;
- Use of pro/prebiotics or fibers as dietary supplements or any food/molecule that modifies intestinal transit time 6 weeks before recruitment; use of laxatives 6 weeks before recruitment;
- Specific dietary regimen (e.g., vegan); specific dietary treatment (e.g., high protein);
- Excessive consumption of substances and alcohol; smokers;
- Diagnosis of gastrointestinal disorders, hormonal or thyroid diseases, autoimmune diseases, and/or chronic use of corticosteroids; psychiatric disease; Type 1 or 2 diabetes;
- Use of proton pump inhibitors; antidiabetic drugs or insulin and statins;
- Subjects with insulin sensitivity;
- Pregnant or lactating women;
- Subjects with tooth sensitivity
- Participation in another clinical trial in the last 3 months.
Where it is running
2 locations listed.
- Centro de Apoio Tecnológico Agro Alimentar (CATAA) (facilities temporarily provided by the Affidea clinical analysis center) - Covilha, Portugal
- Centro de Apoio Tecnológico Agro Alimentar (CATAA) - Castelo Branco, Castelo Branco District, Portugal